Qiming Venture Partners and Eight Portfolio Companies Named to China Innovative Drug Decade Honors List
The list aims to honor outstanding institutions, companies, and major innovations that have delivered exceptional performance over the past decade while playing a significant leading and driving role in the upgrade of China's innovative pharmaceutical industry — establishing benchmarks for the sector's next ten-year journey.
Recently, the China Innovative Drug Decade of Glory list was unveiled. The list covers eight categories, including Industry-Leading Investment Institutions, Industry-Leading CRO Companies, Industry-Leading Biotech Companies, and Industry-Leading Innovative Drugs. Based on PharmCube's comprehensive data across the entire innovative drug industry chain, the selections aim to recognize outstanding institutions, enterprises, and major innovations that have achieved excellent results over the past decade while playing a significant leading and driving role in upgrading China's innovative drug industry — and to set benchmarks for the next decade of China's innovative drug sector. Qiming Venture Partners and eight of its portfolio companies made the list.
In the institutional category, Qiming Venture Partners was named to the Industry-Leading Investment Institutions list.
Qiming Venture Partners
Selected for
Industry-Leading Investment Institutions List
In the enterprise category, Qiming portfolio companies Tigermed (300347.SZ, 03347.HK), Frontage Laboratories, and Crown Bioscience were named to the Industry-Leading CRO Companies list; Zai Lab (NASDAQ:ZLAB, 09688.HK), MediLink Therapeutics, Abbisko Therapeutics (02256.HK), Insilico Medicine, and Jacobio Pharmaceuticals (01167.HK) were named to the Industry-Leading Biotech Companies list; and Jacobio's self-developed KRAS G12C inhibitor, Arike® (generic name: glecirasib), was named to the Industry-Leading Innovative Drugs list.
Tigermed, Frontage Laboratories, Crown Bioscience
Selected for
Industry-Leading CRO Companies List
Zai Lab, MediLink Therapeutics, Abbisko Therapeutics
Insilico Medicine, Jacobio Pharmaceuticals
Selected for
Industry-Leading Biotech Companies List
Jacobio KRAS G12C Inhibitor Arike®
(Generic name: glecirasib)
Selected for
Industry-Leading Innovative Drugs List
- Industry-Leading Investment Institutions List
This list comprehensively evaluates investment institutions across multiple dimensions, including fundraising and investment scale, innovative drug investment density, clinical and commercial value of portfolio companies' innovations, and investment patience. The selected institutions distinguished themselves through outstanding investment performance, long-term focus and patience in China's innovative drug sector, and insight into frontier innovation technologies and industry development trends.
- Industry-Leading CRO Companies List
PharmCube comprehensively evaluates CRO companies' contributions to the innovative drug industry and business competitiveness, selecting benchmark enterprises that empower China's pharmaceutical innovation through "value-added services," accelerate innovative drug time-to-market through "efficiency revolutions," and reshape the global innovative drug competitive landscape. The selected companies demonstrate exceptional service quality and scale, strong technical capabilities, forward-looking global footprints, and sustained enablement of industry innovation.
- Industry-Leading Biotech Companies List
PharmCube comprehensively evaluates Biotech companies across multiple dimensions, including comprehensive competitiveness of product pipelines, clinical and commercial value of core products, international expansion, and recognition by investment institutions. The final selections are benchmark Biotech enterprises that have developed globally competitive innovative drugs with exceptional R&D efficiency, achieved commercial expansion and international presence, truly led China's biopharmaceutical wave, and reshaped the global innovative drug landscape.
- Industry-Leading Innovative Drugs List
PharmCube comprehensively evaluates drugs across multiple dimensions, including innovation, clinical value, commercial value, and international competitiveness, selecting benchmark innovative drugs with major technological breakthroughs and differentiated R&D approaches that fill unmet clinical needs or advance treatment paradigms, demonstrating outstanding clinical data and international competitiveness. The selected drugs showcase innovative mechanisms of action, breakthrough clinical efficacy, and significant social and commercial value.
In its selection report, PharmCube noted that investment institutions, with forward-looking industry vision, anchor original innovation and breakthrough technologies, patiently accompany innovative enterprises through their growth, actively connect global resources, and drive China's innovative drugs toward the center of the world stage — serving as the most steadfast companions to innovative drug companies.
The outstanding institutions, enterprises, and major innovations that have emerged over the past decade can inspire more emerging forces committed to addressing clinical needs, becoming pioneers in leading industry upgrades and a mainstay in building China's innovative drug international competitiveness.
Source | PharmCube
Previous Highlights
Qiming Honors | Qiming Venture Partners and 4 portfolio companies selected for the 3rd PharmCube TOP15 Annual Series List Qiming Honors | Qiming Venture Partners ranked #1 Best VC Fund in the Yangtze River Delta Region by China FOF Research Center 2025 Qiming Honors | Qiming Venture Partners selected for China Fund's 2nd China Private Equity & Venture Capital Yinghua Demonstration Cases
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.